Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised, Double-blind, Placebo-controlled, Event Driven, Phase III Study of Rosuvastatin 20 mg Once Daily in the Long Term Prevention of Recurrent Venous Thromboembolism in Patients With Deep Vein Thrombosis or Pulmonary Embolism

NCT01164540 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT01164540
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01164540 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised, Double-blind, Placebo-controlled, Event Driven, Phase III Study of Rosuvastatin 20 mg Once Daily in the Long Term Prevention of Recurrent Venous Thromboembolism in Patients With Deep Vein Thrombosis or Pulmonary Embolism
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Withdrawn
Start date
February 28, 2011
Completion date
March 31, 2013
Enrollment
3,000 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

pulmonary embolism, venous thrombosis